Payment overview · 2025
General Payments
$361.56
14 reported records · 6 companies
Healthcare provider profile · identity verified
Igor A. Talis, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FAR ROCKAWAY, NY · NPI 1457561920
Verified facts
What the public records show
CMS Open Payments records show Igor A. Talis, D.O. received $361.56 in general payments during 2025 across 14 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 832 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $187.33 | 51.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.20 | 22.2% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.54 | 8.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.28 | 5.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.24 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.97 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.56 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $187.33 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $80.20 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 209 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 312 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
209 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
312 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
193 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
832 | 112 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1006 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 934 | 128 |
| Eliquis | Apixaban | 832 | 112 |
| Furosemide | Furosemide | 692 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 682 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 640 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 595 | 85 |
| Losartan Potassium | Losartan Potassium | 555 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 480 | 67 |
| Memantine Hcl Er | Memantine Hcl | 458 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 444 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 86 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 404 | 53 |
| Metformin Hcl | Metformin Hcl | 398 | 64 |
| Carvedilol | Carvedilol | 390 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 388 | 54 |
| Gabapentin | Gabapentin | 351 | 55 |
| Omeprazole | Omeprazole | 339 | 59 |
| Linzess | Linaclotide | 312 | 44 |
| Potassium Chloride | Potassium Chloride | 307 | 56 |
| Trazodone Hcl | Trazodone Hcl | 306 | 54 |
| Mirtazapine | Mirtazapine | 281 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 269 | 96 |
| Quetiapine Fumarate | Quetiapine Fumarate | 259 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 241 | 43 |
| Tradjenta | Linagliptin | 235 | 29 |
| Januvia | Sitagliptin Phosphate | 211 | 30 |
| Allopurinol | Allopurinol | 210 | 30 |
| Creon | Lipase/Protease/Amylase | 209 | 37 |
| Donepezil Hcl | Donepezil Hcl | 205 | 33 |
| Synthroid | Levothyroxine Sodium | 193 | 19 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 191 | 145 |
| Ranolazine Er | Ranolazine | 183 | 28 |
| Vascepa | Icosapent Ethyl | 176 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 171 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 145 | 29 |
| Alendronate Sodium | Alendronate Sodium | 144 | 20 |
| Simvastatin | Simvastatin | 142 | 29 |
| Repaglinide | Repaglinide | 139 | 21 |
| Xarelto | Rivaroxaban | 137 | 18 |
| Levetiracetam | Levetiracetam | 135 | 16 |
| Nifedipine Er | Nifedipine | 134 | 14 |
| Spironolactone | Spironolactone | 134 | 22 |
| Buspirone Hcl | Buspirone Hcl | 130 | 18 |
| Azithromycin | Azithromycin | 128 | 110 |
| Glipizide | Glipizide | 127 | 17 |
| Memantine Hcl | Memantine Hcl | 126 | 26 |
| Lisinopril | Lisinopril | 123 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 117 | 18 |
| Entresto | Sacubitril/Valsartan | 117 | 19 |
| Famotidine | Famotidine | 108 | 29 |
| Lactulose | Lactulose | 105 | 58 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 78 |
| Silver Sulfadiazine | Silver Sulfadiazine | 104 | 73 |
| Digoxin | Digoxin | 101 | 15 |
| Ezetimibe | Ezetimibe | 97 | 16 |
| Valsartan | Valsartan | 97 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 70 |
| Clotrimazole | Clotrimazole | 96 | 71 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 72 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 94 | 11 |
| Doxepin Hcl | Doxepin Hcl | 93 | 13 |
| Mupirocin | Mupirocin | 93 | 66 |
| Trulance | Plecanatide | 93 | 16 |
| Finasteride | Finasteride | 92 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 91 | 13 |
| Azelastine Hcl | Azelastine Hcl | 87 | 75 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 86 | 33 |
| Atenolol | Atenolol | 85 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 21 |
| Jardiance | Empagliflozin | 82 | 11 |
| Cefdinir | Cefdinir | 81 | 65 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 78 | 54 |
| Montelukast Sodium | Montelukast Sodium | 76 | 13 |
| Temazepam | Temazepam | 75 | 11 |
| Torsemide | Torsemide | 74 | 13 |
| Belsomra | Suvorexant | 70 | 15 |
| Zenpep | Lipase/Protease/Amylase | 70 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 15 |
| Dutasteride | Dutasteride | 69 | 11 |
| Enalapril Maleate | Enalapril Maleate | 69 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 52 |
| Telmisartan | Telmisartan | 69 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 68 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 67 | 19 |
| Labetalol Hcl | Labetalol Hcl | 67 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | suppressed |
| Clonazepam | Clonazepam | 60 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Calcitriol | Calcitriol | 57 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 47 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 29 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 45 | 22 |
| Procrit | Epoetin Alfa | 45 | 16 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | 11 |
| Risperidone | Risperidone | 44 | 11 |
| Tramadol Hcl | Tramadol Hcl | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | 16 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 41 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 15 |
| Ammonium Lactate | Ammonium Lactate | 34 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 31 |
| Methimazole | Methimazole | 34 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 34 | 17 |
| Ssd | Silver Sulfadiazine | 34 | 20 |
| Constulose | Lactulose | 33 | 20 |
| Nystatin | Nystatin | 33 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | 16 |
| Ursodiol | Ursodiol | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Enulose | Lactulose | 28 | 13 |
| Celecoxib | Celecoxib | 27 | 21 |
| Ozempic | Semaglutide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ramelteon | Ramelteon | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Letrozole | Letrozole | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Bystolic | Nebivolol Hcl | 23 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 17 | 13 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Moxifloxacin | Moxifloxacin Hcl | 17 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 16 | 13 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | 13 |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 13 |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.56 · 14 records | Otsuka America Pharmaceutical, Inc. | CAMZYOS, CREON, IBSRELA, LINZESS, NUPLAZID, REXULTI, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error